keyword
https://read.qxmd.com/read/38534887/navigating-lymphomas-through-bcr-signaling-and-double-hit-insights-overview
#1
REVIEW
Antonella Argentiero, Alessandro Andriano, Donatello Marziliano, Vanessa Desantis
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating from B, T, or NK lymphocytes. They represent approximately 4-5% of new cancer cases and are classified according to the revised WHO system based on cell lineage, morphology, immunophenotype, and genetics. Diagnosis requires adequate biopsy material, though integrated approaches are used for leukemic presentations. Molecular profiling is improving classification and identifying prognostic markers. Indolent NHLs, such as follicular lymphoma and marginal zone lymphoma, typically pursue a non-aggressive clinical course with long survival...
March 21, 2024: Hematology Reports
https://read.qxmd.com/read/38532527/management-of-vaccinations-in-patients-with-non-hodgkin-lymphoma
#2
REVIEW
Michele Merli, Andrea Costantini, Silvio Tafuri, Davide Fiore Bavaro, Carla Minoia, Erika Meli, Stefano Luminari, Guido Gini
Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients...
March 26, 2024: British Journal of Haematology
https://read.qxmd.com/read/38532234/stigma-risks-and-benefits-of-medicinal-cannabis-use-among-australians-with-cancer
#3
JOURNAL ARTICLE
Julia N Morris, Jessica Loyer, Jason Blunt
PURPOSE: People with cancer who use medicinal cannabis do so despite risks associated with limited clinical evidence, legalities, and stigma. This study investigated how Australians with cancer rationalise their medicinal cannabis use despite its risks. METHODS: Ten adults (5 males and 5 females; mean age of 53.3) who used cannabis medicinally for their cancer were interviewed in 2021-2022 about how they used and accessed the substance, attitudes and beliefs underpinning their use, and conversations with others about medicinal cannabis...
March 27, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38531903/cancer-incidence-trends-in-new-york-state-and-associations-with-common-population-level-exposures-2010-2018-an-ecological-study
#4
JOURNAL ARTICLE
Haokun Yuan, Rebecca D Kehm, Josephine M Daaboul, Susan E Lloyd, Jasmine A McDonald, Lina Mu, Parisa Tehranifar, Kai Zhang, Mary Beth Terry, Wan Yang
The impact of common environmental exposures in combinations with socioeconomic and lifestyle factors on cancer development, particularly for young adults, remains understudied. Here, we leveraged environmental and cancer incidence data collected in New York State at the county level to examine the association between 31 exposures and 10 common cancers (i.e., lung and bronchus, thyroid, colorectal, kidney and renal pelvis, melanoma, non-Hodgkin lymphoma, and leukemia for both sexes; corpus uteri and female breast cancer; prostate cancer), for three age groups (25-49, 50-69, and 70-84 year-olds)...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38531760/car-t-cell-therapy-a-collaboration-between-authorized-treatment-centers-and-community-oncologists
#5
REVIEW
Michael R Bishop, Gary E Kay
With the approval of the first CAR T-cell products for hematological malignancies in 2017, these autologous cell therapies have changed the treatment paradigm for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL), who have a poor prognosis and few effective treatment options. Despite the demonstrated clinical benefit in patients with r/r diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, many patients who are eligible for CAR T-cell therapies do not receive them or are treated with CAR T cells as a later line of therapy at advanced stages of disease...
February 22, 2024: Seminars in Oncology
https://read.qxmd.com/read/38531057/impact-of-race-and-social-determinants-of-health-on-outcomes-in-patients-with-aggressive-b-cell-nhl-treated-with-car-t
#6
JOURNAL ARTICLE
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran A Nizamuddin, Shuo Ma, Jonathan Moreira, Jane N Winter, Barbara Pro, Deborah M Stephens, Alexey V Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Healthcare disparities driven by multiple social, economic, and/or environmental factors lead to inequalities in health outcomes. CAR-T cell immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of the convergence of race and social determinants of health on outcomes for patients treated with CAR-T therapy. We examined the impact of interactions between race and insurance type on health care utilization and outcomes in patients treated with CAR-T for aggressive B-NHL...
March 26, 2024: Blood Advances
https://read.qxmd.com/read/38529931/acute-kidney-injury-in-children-with-lymphoma
#7
JOURNAL ARTICLE
Hejia Zhang, Yanlong Duan, Xiaoxue Li, Zhi Chen, Xiaorong Liu
OBJECTIVE: To analyze the epidemiology of acute kidney injury (AKI) in children with lymphoma and to assess the incidence, risk profile of AKI, and effects on renal function in children with lymphoma during their first 30 days of hospitalization. MATERIALS AND METHODS: This was a retrospective screen of electronic hospital and laboratory databases to select hospitalized children who were first diagnosed and treated for lymphoma at Beijing Children's Hospital between 2020 and 2021...
March 26, 2024: Clinical Nephrology
https://read.qxmd.com/read/38526250/a-study-on-geographic-correlation-between-indoor-radon-exposure-and-leukemia-incidence-in-canada
#8
JOURNAL ARTICLE
Jing Chen
In Canada, leukemia is diagnosed at a rate of 15 cases per 100,000 persons and accounts for about 3% of all new primary cancers. In this study, geographical correlation between residential radon exposure and leukemia incidence was investigated at a provincial level with more accurate long-term radon measurement data in 21,330 homes and 10-y (2000-2009) age standardized incidence rates per 100,000 population for various subtypes of leukemia. The analyses showed that the incidence rate of non-Hodgkin lymphoma is statistically significantly correlated with average indoor radon (222Rn) concentration for Canadian females (p = 0...
May 1, 2024: Health Physics
https://read.qxmd.com/read/38524523/heterochronous-multiple-primary-prostate-cancer-and-lymphoma-a-case-report
#9
Jin-Long Liang, Yu-Qing Bu, Li-Li Peng, Hong-Zhen Zhang
BACKGROUND: Multiple primary malignant tumors (MPMTs) are rare type of cancer, especially when solid tumors are the first and lymphoma is the second primary malignancy. We report a patient with heterochronous MPMTs consisting of prostate cancer and rectal diffuse large B-cell lymphoma (DLBCL). CASE SUMMARY: We report a 77-year-old male patient diagnosed with prostate cancer who was treated with radiation therapy and one year of endocrine therapy with bicalutamide (50 mg per day) and an extended-release implant of goserelin (1/28 d)...
March 6, 2024: World Journal of Clinical Cases
https://read.qxmd.com/read/38524018/t-cell-lymphoblastic-lymphoma-unveiling-as-superior-vena-cava-syndrome-in-a-19-year-old-male
#10
Rinkle Gemnani, Keyur Saboo, Rajvardhan Patil, Sunil Kumar, Sourya Acharya
Superior vena cava syndrome (SVCS) is a collection of signs and symptoms resulting from superior vena cava obstruction which is either partial or complete. SVCS is a rare clinical entity, often associated with various malignancies. T-cell lymphoblastic lymphoma (T-LBL) primarily of the mediastinum (thymus) is a rare and aggressive non-Hodgkin lymphoma that can lead to SVCS. We discuss the case of a 19-year-old male who arrived at our emergency department with symptoms of cough, breathlessness, and facial puffiness along with swelling in the right anterior mediastinum for two weeks suggestive of acute SVCS...
February 2024: Curēus
https://read.qxmd.com/read/38523995/nasal-type-natural-killer-t-cell-lymphoma-with-inaugural-testicular-presentation-in-a-young-patient
#11
Oumayma Mnafe, Eddou Hicham
Nasal-type natural killer/T-cell lymphoma is a rare non-Hodgkin's malignant lymphoma. A distinct clinicopathological entity associated with the Epstein-Barr virus, it typically presents with otorhinolaryngeal symptomatology. We report a rare case of a 24-year-old patient with nasal-type lymphoma with an atypical inaugural testicular presentation associated with the discovery of bilateral adrenal involvement.
February 2024: Curēus
https://read.qxmd.com/read/38523827/pediatric-non-hodgkin-lymphoma-as-a-rare-cause-of-spinal-cord-injury-when-lymphoma-hides-in-the-canal
#12
Daniele Zama, Egidio Candela, Gennaro Pagano, Francesco Venturelli, Fraia Melchionda, Francesco Toni, Mino Zucchelli, Andrea Pession
KEY CLINICAL MESSAGE: Spinal cord compression from non-Hodgkin lymphoma (NHL) should be considered as a potential diagnosis in cases of acute signs of myelopathy in pediatric patients. ABSTRACT: Spinal cord compression in pediatric non-Hodgkin lymphoma (NHL) is a rare presentation with potential diagnostic challenges. We report on two pediatric patients with NHL who exhibited myelopathy signs as initial presentation. Considering NHL as a differential diagnosis in pediatric patients presenting with spinal cord compression is crucial for optimizing the outcome of these patients...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38521840/post-marketing-surveillance-of-the-safety-and-effectiveness-of-nivolumab-for-classic-hodgkin-lymphoma-in-japan
#13
JOURNAL ARTICLE
Akira Kawasaki, Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, Tomohiro Hoshino, Ayumi Akamatsu, Akito Kakuuchi, Kensei Tobinai
Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness of nivolumab treatment for up to 12 months in patients with relapsed/refractory cHL. Of 304 registered patients, 288 were included in safety analyses and 282 in effectiveness analyses. There were 191 (66.3%) male patients, median age was 64.0 years, and 54 patients (18...
March 23, 2024: International Journal of Hematology
https://read.qxmd.com/read/38521835/outcome-differences-by-sex-in-oncology-clinical-trials
#14
JOURNAL ARTICLE
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin
Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472/89,221 oncology clinical trials (0.5%) had curated post-treatment sex comparisons. Among 288 trials with comparisons of survival, outcome, or response, 16% report males having statistically significant better survival outcome or response, while 42% reported significantly better survival outcome or response for females...
March 23, 2024: Nature Communications
https://read.qxmd.com/read/38521411/graft-failure-incidence-risk-factors-and-outcomes-in-patients-undergoing-non-myeloablative-allogeneic-hematopoietic-cell-transplantation-using-post-transplant-cyclophosphamide
#15
JOURNAL ARTICLE
Jonaphine Rae Mata, Marianna Zahurak, Natalie Rosen, Amy E DeZern, Richard J Jones, Alexander J Ambinder
BACKGROUND: Graft failure (GF) is a major complication of allogeneic hematopoietic cell transplantation (alloHCT) that results in significant morbidity and mortality. Post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has emerged as an effective regimen across the spectrum of donor-match settings, but few studies have investigated the characteristics of GF in the setting of PTCy-based GVHD prophylaxis. OBJECTIVES: The objective was to detail the incidence, clinical features, risk factors, and outcomes for patients with primary graft failure (PGF) and secondary graft failure (SGF)...
March 21, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38519055/molecular-assessment-of-intratumoral-immune-cell-subsets-and-potential-mechanisms-of-resistance-to-odronextamab-a-cd20%C3%A3-cd3-bispecific-antibody-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma
#16
JOURNAL ARTICLE
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S Topp, Rajat Bannerji, Johannes Duell, Ranjana H Advani, Dina M Flink, Aafia Chaudhry, Gavin Thurston, Srikanth R Ambati, Vladimir Jankovic
BACKGROUND: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/major histocompatibility complex interaction. Phase I results in patients with R/R B-NHL demonstrated that odronextamab monotherapy could achieve deep and durable responses with a generally manageable safety profile (ELM-1; NCT02290951)...
March 21, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38515220/diagnostic-dilemma-in-maxillofacial-pathologies-a-case-series
#17
JOURNAL ARTICLE
Pavithra Sarda, Prashanthi Gurram, Karthik Ramakrishnan, Vivek Narayanan, Saravanan Chandran, Divya Vinayachandran
BACKGROUND: Head and neck are a site of numerous pathologies with different aetiologies and presentations. Rare pathologies, although infrequent still do exist. Diagnostic dilemma in maxillofacial pathologies can be the most challenging situation. Dealing with uncertainty, although difficult, is a reality in surgical practice. Being thorough, attentive to details and clues, and maintaining an open mind are critical strategies in the approach to such a patient. CASE PRESENTATION: In our paper we are reporting a spectrum of 4 unusual variants of head and neck pathologies, whose age and sex were 52 years/ M, 37 years/F, 41 years/ F, 30 years/F respectively...
March 21, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38513186/increasing-annual-cancer-incidence-in-patients-age-20-49-years-a-real-data-study
#18
JOURNAL ARTICLE
Nuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, Sofía Ruiz-Medina, Javier Garcia-Corbacho, Jose Carlos Benitez, Maria Emilia Dominguez-Recio, Esperanza Torres, Lucia Oliva, Manuel Zalabardo, Antonio Rueda, Emilio Alba
PURPOSE: Data from population-based studies have shown an increased incidence of certain types of neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived from other real-world data sources. In a nonpopulation registry, we analyzed changes in the incidence of several neoplasms in successive generations. METHODS: This cross-sectional study included all patients with a cancer diagnosis registered in one university hospital in Málaga, Spain, between 1998 and 2021, and 18 neoplasms were analyzed...
March 2024: JCO global oncology
https://read.qxmd.com/read/38512531/primary-vs-pre-emptive-anti-seizure-medication-prophylaxis-in-anti-cd19-car-t-cell-therapy
#19
JOURNAL ARTICLE
Umberto Pensato, Federica Pondrelli, Chiara de Philippis, Gian Maria Asioli, Alessandra Crespi, Alessandro Buizza, Daniele Mannina, Beatrice Casadei, Enrico Maffini, Laura Straffi, Simona Marcheselli, Pier Luigi Zinzani, Francesca Bonifazi, Maria Guarino, Stefania Bramanti
INTRODUCTION: Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure medication (ASM) prevention strategy has not been thoroughly investigated. METHODS: Consecutive patients affected by refractory non-Hodgkin lymphoma who received anti-CD19 CAR T-cells were included. Patients were selected and assessed using similar internal protocols. ASM was started either as a primary prophylaxis (PP-group) before CAR T-cells infusion or as a pre-emptive therapy (PET-group) only upon the onset of neurotoxicity development...
March 21, 2024: Neurological Sciences
https://read.qxmd.com/read/38511807/myelotoxicity-and-kidney-dysfunction-related-to-the-use-of-trimethoprim-sulfamethoxazole-for-the-treatment-of-pneumocystis-jirovecii-pneumonia-a-case-report-of-severe-adverse-events-with-a-common-drug
#20
Isabel Cristina Melo Mendes, Roxana Flores Mamani, David Richer Araujo Coelho, Clarisse Pimentel
Trimethoprim-sulfamethoxazole (TMP-SMX) is the primary therapeutic option for Pneumocystis jirovecii pneumonia (PCP). Gastrointestinal symptoms and cutaneous rash are common side effects, with hyperkalemia being uncommon in patients without kidney dysfunction, and myelotoxicity being even rarer. We present the case of a male patient with hypertension and a recent diagnosis of non-Hodgkin lymphoma, undergoing rituximab treatment for two months. He was admitted to the intensive care unit due to dyspnea, tachypnea, and pleuritic pain, requiring mechanical ventilation...
2024: Revista do Instituto de Medicina Tropical de São Paulo
keyword
keyword
4732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.